지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2012.1
- 수록면
- 107 - 115 (9page)
이용수
초록· 키워드
오류제보하기
The in vivo muscarinic receptor binding of antimuscarinic agents (oxybutynin, solifenacin, tolterodine, and imidafenacin) used to treat urinary dysfunction in patients with overactive bladder is reviewed. Transdermal administration of oxybutynin in rats leads to significant binding of muscarinic receptors in the bladder without long-term binding in the submaxillary gland and the abolishment of salivation evoked by oral oxybutynin. Oral solifenacin shows significant and long-lasting binding to muscarinic receptors in mouse tissues expressing the M3 subtype. Oral tolterodine binds more selectively to muscarinic receptors in the bladder than in the submaxillary gland in mice. The muscarinic receptor binding of oral imidafenacin in rats is more selective and longer-lasting in the bladder than in other tissues such as the submaxillary gland, heart, colon, lung, and brain, suggesting preferential muscarinic receptor binding in the bladder. In vivo quantitative autoradiography with (+)N-[11C]methyl-3-piperidyl benzilate in rats shows significant occupancy of brain muscarinic receptors with the intravenous injection of oxybutynin, solifenacin, and tolterodine. The estimated in vivo selectivity in brain is significantly greater for solifenacin and tolterodine than for oxybutynin. Imidafenacin occupies few brain muscarinic receptors. Similar findings for oral oxybutynin were observed with positron emission tomography in conscious rhesus monkeys with a significant disturbance of short-term memory. The newer generation of antimuscarinic agents may be advantageous in terms of bladder selectivity after systemic administration.
목차
등록된 정보가 없습니다.
참고문헌 (24)
참고문헌 신청
Anderson KE / 1993 / Pharmacology of lower urinary tract smooth muscles and penile erectile tissues / Pharmacol Rev 45 : 253 ~ 308
Anderson RU / 1999 / Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group / J Urol 161 : 1809 ~ 1812
Andersson KE / 2004 / Antimuscarinics for treatment of overactive bladder / Lancet Neurol 3 : 46 ~ 53
Chapple CR / 1996 / Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience / Eur Urol 29 : 129 ~ 144
Davila GW / 2001 / A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immedi
Anderson RU / 1999 / Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group / J Urol 161 : 1809 ~ 1812
Andersson KE / 2004 / Antimuscarinics for treatment of overactive bladder / Lancet Neurol 3 : 46 ~ 53
Chapple CR / 1996 / Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience / Eur Urol 29 : 129 ~ 144
Davila GW / 2001 / A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immedi
이 논문의 저자 정보
최근 본 자료
댓글(0)
0